Neurocrine Biosciences Boosts Revenue 39% on Strong Drug Sales and Soleno Acquisition — Neurocrine Biosciences, Inc.

Event summary

Neurocrine Biosciences reported $959 million in Q2 2026 revenue, up 39% YoY, driven by INGREZZA and CRENESSITY sales growth.
INGREZZA net product sales grew 15% YoY to $716 million, with full-year guidance raised to $2.825–$2.875 billion.
CRENESSITY sales surged 247% YoY to $184 million, supported by high reimbursement rates.
Completed $2.9 billion acquisition of Soleno Therapeutics in May 2026, adding VYKAT XR for Prader-Willi syndrome treatment.

The big picture

Neurocrine Biosciences is leveraging strategic acquisitions and a robust pipeline to solidify its position in neurology and endocrinology. The Soleno acquisition expands its rare disease portfolio, while strong sales performance across key products underscores its commercial execution capabilities. The company's focus on innovation and long-term value creation positions it for continued growth in competitive biotech markets.

What we're watching

Pipeline Progress: The success of Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia will determine Neurocrine's long-term growth trajectory.
Integration Challenges: Neurocrine must effectively integrate Soleno Therapeutics to maximize the value of VYKAT XR and maintain momentum in its expanded portfolio.
Commercial Execution: The company's ability to sustain sales growth for INGREZZA, CRENESSITY, and VYKAT XR will be critical in meeting updated financial guidance.